









Markets
/
Stocks
/
nasdaq-tlry
/

Tilray Brands Inc

TLRY

1.260USD

+0.070+5.88%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.34BMarket Cap

LossP/E TTM



Tilray Brands Inc

1.260

+0.070+5.88%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

104 / 175

Overall Ranking

273 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Hold

Current Rating

1.014

Target Price

-16.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30.96% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 50.53.

Overvalued

The company’s latest PE is -0.48, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 103.84M shares, decreasing 29.50% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.26M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.62.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.87, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 224.53M, representing a year-over-year decrease of 2.33%, while its net profit experienced a year-over-year decrease of 3909.18%.

Score

Industry at a Glance

Previous score

7.87

Change



Financials

6.08

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.20

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.35

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.48, which is 58.80% below the recent high of -0.77 and -677.11% above the recent low of -3.77.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.60, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Tilray Brands Inc is 0.85, with a high of 2.00 and a low of 0.60.

Score

Industry at a Glance

Previous score

6.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Hold

Current Rating

1.014

Target Price

-14.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Tilray Brands Inc

TLRY

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.78, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 1.49 and the support level at 0.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.89

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.051

Neutral

RSI(14)

55.269

Neutral

STOCH(KDJ)(9,3,3)

65.284

Buy

ATR(14)

0.100

Low Volatility

CCI(14)

4.960

Neutral

Williams %R

65.957

Sell

TRIX(12,20)

0.779

Sell

StochRSI(14)

76.292

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.154

Buy

MA10

1.146

Buy

MA20

1.214

Buy

MA50

0.931

Buy

MA100

0.684

Buy

MA200

0.813

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 9.50%, representing a quarter-over-quarter decrease of 12.16%. The largest institutional shareholder is The Vanguard, holding a total of 4.26M shares, representing 0.38% of shares outstanding, with 15.46% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tidal Investments LLC

25.20M

+137.80%

Simon (Irwin D)

3.78M

+16.33%

Susquehanna International Group, LLP

4.93M

-52.97%

The Vanguard Group, Inc.

Star Investors

4.07M

-2.35%

Global X Investments Canada Inc.

4.39M

-0.37%

Morgan Stanley & Co. LLC

2.24M

-18.80%

Mirae Asset Global Investments (USA) LLC

2.68M

+8.67%

State Street Global Advisors (US)

2.14M

+1.77%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.03, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.